Drug Trial Radar · NCT06885840
Study of MCLA-129 in the Treatment of Advanced Non-small Cell Lung Cancer with AGA and MET Amplification.
Last checked: Nov 19, 2026Latest source record: Mar 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Mar 31, 2025
Primary completion
Apr 2028
Study completion Sep 2028
Sponsor
- Lead sponsor
- Betta Pharmaceuticals Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 20, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, open-label, phase II clinical study of MCLA-129 as monotherapy in patients with advanced non-small cell lung cancer (NSCLC) with actionable gene alterations and MET amplification to evaluate the efficacy, safety, pharmacokinetic characteristics of MCLA-129.
Conditions
- Non-Small Cell Lung Cancer
Interventions
MCLA-129Drug
MCLA-129 will be administered by intravenous infusion on the 28-day treatment cycle.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall Response Rate (ORR)Time frame: From date of first treatment every 6 weeks until disease progression, death or withdrawal, whichever came first, approximately 2 years
Locations
20 sites in 1 country. Site status is shown where the registry gives one.
Beijing Chest Hospital
Beijing, China
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
The First Hospital of Lanzhou University
Lanzhou, Gansu, China
Dongguan People's Hospital
Dongguan, Guangdong, China
Foshan First People's Hospital
Foshan, Guangdong, China
Guangdong General Hospital
Guangzhou, Guangdong, China
Hebei University Affiliated Hospital
Baoding, Hebei, China
Harbin Medical University Affiliated Cancer Hospital
Harbin, Heilongjiang, China
Henan Cancer Hospital
Zhengzhou, Henan, China
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology
Wuhan, Hubei, China
Hunan Cancer Hospital
Changsha, Hunan, China
Nantong Cancer Hospital
Nantong, Jiangsu, China
Jilin Cancer Hospital
Changchun, Jilin, China
The First Hospital of Jilin University
Changchun, Jilin, China
The First Affiliated Hospital of China Medical University
Shenyang, Liaoning, China
Shandong Cancer Hospital
Jinan, Shandong, China
The First Affiliated Hospital of Xi'an Jiaotong University
Xi’an, Shanxi, China
Tianjin Cancer Hospital
Tianjin, Tianjin Municipality, China
The First Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
The Second Affiliated Hospital of Zhejiang University School of Medicine
Hangzhou, Zhejiang, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.